Corrie R. Belanger

Corrie R. Belanger

Auto-generated profile, based on publicly available information

Corrie R. Belanger

Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
CBCorrie R. Belanger
Corrie R. Belanger
RHRobert E. W. Hancock
Robert E. W. Hancock

22 August 2018 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
MDMelanie Dostert
Melanie Dostert
CBCorrie R. Belanger
Corrie R. Belanger
RHRobert E. W. Hancock
Robert E. W. Hancock
Highly antibiotic resistant, microbial communities, referred to as biofilms, cause various life-threatening infections in humans. At least two-thirds of all clinical infections are biofilm associated, and antibiotic therapy regularly fails to cure patients. Anti-biofilm peptides represent a promising approach to treat these infections by targeting biofilm-specific characteristics such as highly conserved regulatory mechanisms. They are being considered for clinical application and we discuss here key factors in discovery, design, and application, particularly the implementation of host-mimicking conditions, that are required to enable the successful advancement of potent anti-biofilm peptides from the bench to the clinic.

1 October 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
NANoushin Akhoundsadegh
Noushin Akhoundsadegh
CBCorrie R. Belanger
Corrie R. Belanger
RHRobert E. W. Hancock
Robert E. W. Hancock
Infections caused by drug-resistant Gram-negative bacilli are a severe global health threat, limiting effective drug choices for treatment. In this study, polymyxin analogs designed to have reduced nephrotoxicity, direct activity, and potentiating activity were assessed for inhibition and outer membrane interaction kinetics against wild-type (WT) and polymyxin or multidrug-resistant (MDR) Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. In MIC assays, two polymyxin B (PMB) analogs (SPR1205 and SPR206) and a polymyxin E analog (SPR946), with shortened peptide side chains and branched aminobutyryl N termini, exhibited promising activity compared with PMB and previously tested control polymyxin analogs SPR741 and polymyxin B nonapeptide (PMBN). Using dansyl-polymyxin (DPX) binding to assess the affinity of interaction with lipopolysaccharide (LPS), purified or in the context of intact cells, SPR206 exhibited similar affinities to PMB but higher affinities than the other SPR analogs. Outer membrane permeabilization measured by the 1-N-phenyl-napthylamine (NPN) assay did not differ significantly between the polymyxin analogs. Moreover, Hill numbers were greater than 1 for most of the compounds tested on E. coli and P. aeruginosa strains which indicates that the disruption of the outer membrane by one molecule of compound cooperatively enhances the subsequent interactions of other molecules against WT and MDR strains. The high activity demonstrated by SPR206 as well as its ability to displace LPS and permeabilize the outer membrane of multiple strains of Gram-negative bacilli while showing cooperative potential with other membrane disrupting compounds supports further research with this polymyxin analog.

14 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CBCorrie R. Belanger
Corrie R. Belanger
ALAmy Huei-Yi Lee
Amy Huei-Yi Lee
DPDaniel Pletzer
Daniel Pletzer
BDBhavjinder Kaur Dhillon
Bhavjinder Kaur Dhillon
RFReza Falsafi
Reza Falsafi
RHRobert E. W. Hancock
Robert E. W. Hancock
Significance: The host environment in which infection occurs plays a crucial role in the interaction between Pseudomonas aeruginosa and antibiotic treatments. To make up for the lack of new antibiotics, alternative approaches, such as combination therapy and discovery of novel activity of known antibiotics in the host environment, are vital for treatment of pathogens such as P. aeruginosa. This research demonstrates how in vitro conditions that closely mimic human infection more accurately reflect the antimicrobial activity of antibiotics. We have shown that azithromycin (AZM) has increased activity and synergy with synthetic peptides in physiologically relevant in vitro conditions and in vivo. Furthermore, this research also provides potential alternative mechanisms for the activity of AZM against P. aeruginosa .

1 January 2018
Verified
Book Chapter
Closed access
ESEvelyn Sun
Evelyn Sun
CBCorrie R. Belanger
Corrie R. Belanger
EHEvan F. Haney
Evan F. Haney
RHRobert E.W. Hancock
Robert E.W. Hancock

7 April 2017 in Emerging Topics in Life Sciences
Verified
Journal Article
Closed access
PDF file
CBCorrie R. Belanger
Corrie R. Belanger
SMSarah C. Mansour
Sarah C. Mansour
DPDaniel Pletzer
Daniel Pletzer
RHRobert E. W. Hancock
Robert E. W. Hancock
Biofilms represent an adaptive lifestyle where microbes grow as structured aggregates in many different environments, e.g. on body surfaces and medical devices. They are a profound threat in medical (and industrial) settings and cause two-thirds of all infections. Biofilm bacteria are especially recalcitrant to common antibiotic treatments, demonstrating adaptive multidrug resistance. For this reason, novel methods to eradicate or prevent biofilm infections are greatly needed. Recent advances have been made in exploring alternative strategies that affect biofilm lifestyle, inhibit biofilm formation, degrade biofilm components and/or cause dispersal. As such, naturally derived compounds, molecules that interfere with bacterial signaling systems, anti-biofilm peptides and phages show great promise. Their implementation as either stand-alone drugs or complementary therapies has the potential to eradicate resilient biofilm infections. Additionally, altering the surface properties of indwelling medical devices through bioengineering approaches has been examined as a method for preventing biofilm formation. There is also a need for improving current biofilm detection methods since in vitro methods often do not accurately measure live bacteria in biofilms or mimic in vivo conditions. We propose that the design and development of novel compounds will be enabled by the improvement and use of appropriate in vitro and in vivo models.